Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.

Patel M, Simon JM, Iglesia MD, Wu SB, McFadden AW, Lieb JD, Davis IJ.

Genome Res. 2012 Feb;22(2):259-70. doi: 10.1101/gr.125666.111. Epub 2011 Nov 15.

2.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL.

Cancer Genet. 2011 Jul;204(7):351-65. doi: 10.1016/j.cancergen.2011.07.008. Review.

3.

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Theisen ER, Pishas KI, Saund RS, Lessnick SL.

Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124. Review.

4.

Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Lessnick SL, Ladanyi M.

Annu Rev Pathol. 2012;7:145-59. doi: 10.1146/annurev-pathol-011110-130237. Epub 2011 Sep 19. Review.

5.

Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.

Kovar H.

Expert Opin Ther Targets. 2014 Nov;18(11):1315-28. doi: 10.1517/14728222.2014.947963. Epub 2014 Aug 27. Review.

PMID:
25162919
6.

EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.

Ban J, Siligan C, Kreppel M, Aryee D, Kovar H.

Adv Exp Med Biol. 2006;587:41-52. Review.

PMID:
17163154
7.

Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Erkizan HV, Uversky VN, Toretsky JA.

Clin Cancer Res. 2010 Aug 15;16(16):4077-83. doi: 10.1158/1078-0432.CCR-09-2261. Epub 2010 Jun 14. Review.

8.

Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.

Owen LA, Lessnick SL.

Cell Cycle. 2006 Sep;5(18):2049-53. Epub 2006 Sep 15. Review.

PMID:
16969112
9.

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.

Oncotarget. 2016 Feb 23;7(8):8613-24. doi: 10.18632/oncotarget.6937. Review.

10.

Structure-function based molecular relationships in Ewing's sarcoma.

Todorova R.

Biomed Res Int. 2015;2015:798426. doi: 10.1155/2015/798426. Epub 2015 Jan 22. Review.

11.

Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Lawlor ER, Sorensen PH.

Crit Rev Oncog. 2015;20(3-4):155-71. Review.

12.

The ets transcription factor Fli-1 in development, cancer and disease.

Li Y, Luo H, Liu T, Zacksenhaus E, Ben-David Y.

Oncogene. 2015 Apr 16;34(16):2022-31. doi: 10.1038/onc.2014.162. Epub 2014 Jun 9. Review.

13.

Ewing sarcoma protein: a key player in human cancer.

Paronetto MP.

Int J Cell Biol. 2013;2013:642853. doi: 10.1155/2013/642853. Epub 2013 Sep 3. Review.

14.

Gene translocations in musculoskeletal neoplasms.

Krishnan B, Khanna G, Clohisy D.

Clin Orthop Relat Res. 2008 Sep;466(9):2131-46. doi: 10.1007/s11999-008-0342-0. Epub 2008 Jun 20. Review.

Supplemental Content

Support Center